• Profile

Sodium-glucose co-transporter-2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study

Journal of Diabetes Investigation Feb 10, 2022

In a real-world clinical setting of type 2 diabetes patients, sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was not associated with an increase in fracture risk.

  • The Korean National Health Insurance Service database was used to ascertain if SGLT2i were associated with elevated fracture risk in adults with type 2 diabetes than dipeptidyl peptidase-4 inhibitors (DPP-4i).

  • Propensity score matching was done on 478,826 new users of an SGLT2 inhibitor or DPP-4 inhibitor, and post-propensity score matching on > 80 covariates, 84,460 persons were initiated on SGLT2i or DPP-4i, with 42,230 in each treatment group.

  • In both as-treated (AT) and intention-to-treat (ITT) analyses, SGLT2i initiation was not associated with elevated fracture risk (AT: hazard ratio 0.98; ITT: hazard ratio 0.94).

  • Subgroup analyses revealed absence of significant interaction between the individuals' age, gender, fracture history, or thiazolidinedione usage, suggesting that none of these variables seemed to be effect modifiers in the link between SGLT2i and fractures.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen